Structural insight into the unique properties of adeno-associated: Virus serotype 9

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6947-6958

  DiMattia, Michael A ^a,c   Nam, Hyun Joo ^a,d   Van Vliet, Kim ^a   Mitchell, Matthew ^a   Bennett, Antonette ^a   Gurda, Brittney L ^a,e   McKenna, Robert ^a   Olson, Norman H ^b   Sinkovits, Robert S ^b,f   Potter, Mark ^a   Byrne, Barry J ^a   Aslanidi, George ^a   Zolotukhin, Sergei ^a   Muzyczka, Nicholas ^a   Baker, Timothy S ^b   Agbandje McKenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d The University of Texas at Dallas   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 4; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS SEROTYPE 9; ALPHA HELIX; ARTICLE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CRYSTAL STRUCTURE; IMAGE RECONSTRUCTION; MOLECULAR IMAGING; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN MOTIF; SPECIES COMPARISON; STRUCTURE ANALYSIS; SURFACE PROPERTY; THREE DIMENSIONAL IMAGING; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS MORPHOLOGY; X RAY CRYSTALLOGRAPHY;

CAPSID; CAPSID PROTEINS; CRYOELECTRON MICROSCOPY; CRYSTALLOGRAPHY, X-RAY; DEPENDOVIRUS; IMAGING, THREE-DIMENSIONAL;

ADENO-ASSOCIATED VIRUS; MIRIDAE; PARVOVIRUS;

EID: 84864003612     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07232-11     Document Type: Article

References (83)

1. Agbandje-McKenna M, Kleinschmidt J. 2011. AAV capsid structure and cell interactions. Methods Mol. Biol. 807:47-92.
2. Akache B, et al. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
3. Baker TS, Olson NH, Fuller SD. 1999. Adding the third dimension to virus life cycles: three-dimensional reconstruction of icosahedral viruses from cryo-electron micrographs. Microbiol. Mol. Biol. Rev. 63:862-922.
4. Bell CL, et al. 2011. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121:2427-2435.
5. Belnap DM, Kumar A, Folk JT, Smith TJ, Baker TS. 1999. Lowresolution density maps from atomic models: how stepping "back" can be a step "forward." J. Struct. Biol. 125:166 -175.
6. Berns KI, Linden RM. 1995. The cryptic life style of adeno-associated virus. Bioessays 17:237-245.
7. Bevan AK, et al. 2011. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19:1971-1980.
8. Boutin S, et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704 -712.
9. Bowman VD, et al. 2002. An antibody to the putative aphid recognition site on cucumber mosaic virus recognizes pentons but not hexons. J. Virol. 76:12250 -12258.
10. Brantly ML, et al. 2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U. S. A. 106:16363-16368.
11. Brunger AT. 1993. Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Crystallogr. D Biol. Crystallogr. 49:24 -36.
12. Brunger AT, et al. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
13. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199:381-390.
14. Carrillo-Tripp M, et al. 2009. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37: D436-D442. doi:10.1093/nar/gkn840.
15. Chen VB, et al. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66:12-21.
16. Chuah MK, Vandendriessche T. 2007. Gene therapy for haemophilia "A" and "B" : efficacy, safety and immune consequences. Bull. Mem. Acad. R. Med. Belg. 162:357-361.
17. Collaborative Computational Project. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760- 763.
18. Duque S, et al. 2009. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17: 1187-1196.
19. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126 -2132.
20. Erles K, Sebokova P, Schlehofer JR. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59:406-411.
21. Fechner H, et al. 2008. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J. Mol. Med. (Berl.) 86:987-997.
22. Fisher KJ, et al. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:306 -312.
23. Flotte TR, Carter BJ. 1995. Adeno-associated virus vectors for gene therapy. Gene Ther. 2:357-362.
24. Foust KD, et al. 2009. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27:59-65.
25. Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. 2011. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19:1025-1033.
26. Gao G, et al. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78:6381- 6388.
27. Govindasamy L, et al. 2006. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80:11556 -11570.
28. Havelka WA, Henderson R, Oesterhelt D. 1995. Three-dimensional structure of halorhodopsin at 7 A resolution. J. Mol. Biol. 247:726 -738.
29. Henriques A, et al. 2011. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol. Ther. 19:284 -292.
30. Hester ME, Foust KD, Kaspar RW, Kaspar BK. 2009. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr. Gene Ther. 9:428-433.
31. Inagaki K, et al. 2006. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14:45-53.
32. Kaya Z, Katus HA, Rose NR. 2010. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin. Immunol. 134:80-88.
33. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL Repository and associated resources. Nucleic Acids Res. 37: D387-D392. doi:10.1093/nar/gkn750.
34. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP. 2008. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol. Ther. 16:89 -96.
35. Kleywegt GJ, Jones TA. 1996. xdlMAPMAN and xdlDATAMAN- programs for reformatting, analysis and manipulation of biomacromolecular electron-density maps and reflection data sets. Acta Crystallogr. D Biol. Crystallogr. 52:826-828.
36. Kontou M, et al. 2005. Structural determinants of tissue tropism and in vivo pathogenicity for the parvovirus minute virus of mice. J. Virol. 79: 10931-10943.
37. Kotchey NM, et al. 2011. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19:1079 -1089.
38. Krissinel E, Henrick K. 2004. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60:2256 -2268.
39. Kronenberg S, Kleinschmidt JA, Bottcher B. 2001. Electron cryomicroscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2:997-1002.
40. Lei B, Zhang K, Yue Y, Ghosh A, Duan D. 2010. Adeno-associated virus serotype-9 mediated retinal outer plexiform layer transduction is mainly through the photoreceptors. Adv. Exp. Med. Biol. 664:671- 678.
41. Lerch TF, Xie Q, Chapman MS. 2010. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403:26 -36.
42. Li C, et al. 2012. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 19:288 -294.
43. Li W, et al. 2008. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16:1252-1260.
44. Lochrie MA, et al. 2006. Mutations on the external surfaces of adenoassociated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80:821- 834.
45. McCown TJ. 2011. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 11:181-188.
46. McPhee SW, et al. 2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8:577-588.
47. Miller EB, et al. 2006. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62:1271-1274.
48. Mitchell M, et al. 2009. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 65:715-718.
49. Muzyczka N, Berns K. (ed). 2001. Parvoviridae: the viruses and their replication, 4th ed. Lippincott Williams & Wilkins, New York, NY.
50. Nam HJ, et al. 2011. Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J. Virol. 85: 11791-11799.
51. Nam HJ, et al. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81:12260 -12271.
52. Navaza J. 2001. Implementation of molecular replacement in AMoRe. Acta Crystallogr. D Biol. Crystallogr. 57:1367-1372.
53. Ng R, et al. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84:12945-12957.
54. Pacak CA, Byrne BJ. 2011. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol. Ther. 19:1582-1590.
55. Pacak CA, et al. 2006. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99:e3- e9. doi:10.1161/01.RES.0000237661.18885.f6.
56. Padron E, et al. 2005. Structure of adeno-associated virus type 4. J. Virol. 79:5047-5058.
57. Parrish CR. 2010. Structures and functions of parvovirus capsids and the process of cell infection. Curr. Top. Microbiol. Immunol. 343:149 -176.
58. Peden CS, Burger C, Muzyczka N, Mandel RJ. 2004. Circulating antiwild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78:6344-6359.
59. Pettersen EF, et al. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
60. Pulicherla N, et al. 2011. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19:1070 -1078.
61. Rabinowitz JE, et al. 2004. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78:4421- 4432.
62. Rabinowitz JE, et al. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76:791- 801.
63. Rosenthal PB, Henderson R. 2003. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333:721-745.
64. Sarkar R, et al. 2006. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophiliaAdogs and mice. Hum. Gene Ther. 17:427-439.
65. Scallan CD, et al. 2006. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107:1810 -1817.
66. Schwede T, Kopp J, Guex N, Peitsch MC. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31: 3381-3385.
67. Sharma A, Tovey JC, Ghosh A, Mohan RR. 2010. AAV serotype influences gene transfer in corneal stroma in vivo. Exp. Eye Res. 91:440-448.
68. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286:13532-13540.
69. Suckau L, et al. 2009. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119:1241-1252.
70. Sun B, et al. 2008. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol. Ther. 16:1366 -1371.
71. Vandendriessche T, et al. 2007. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J. Thromb. Haemost. 5:16 -24.
72. Walters RW, et al. 2004. Structure of adeno-associated virus serotype 5. J. Virol. 78:3361-3371.
73. Weitzman MD, Linden RM. 2011. Adeno-associated virus biology. Methods Mol. Biol. 807:1-23.
74. Wobus CE, et al. 2000. Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74:9281-9293.
75. Wriggers W. 2010. Using Situs for the integration of multi-resolution structures. Biophys. Rev. 2:21-27.
76. Xiao W, et al. 1999. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73:3994-4003.
77. Xiao X, Li J, Samulski RJ. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:8098-8108.
78. Xie Q, et al. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99: 10405-10410.
79. Xie Q, Lerch TF, Meyer NL, Chapman MS. 2011. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology 420:10 -19.
80. Xue YQ, et al. 2010. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther. 17:83-94.
81. Yan X, Dryden KA, Tang J, Baker TS. 2007. Ab initio random model method facilitates 3D reconstruction of icosahedral particles. J. Struct. Biol. 157:211-225.
82. Yan X, Sinkovits RS, Baker TS. 2007. AUTO3DEM-an automated and high throughput program for image reconstruction of icosahedral particles. J. Struct. Biol. 157:73- 82.
83. Zhang X, Walker SB, Chipman PR, Nibert ML, Baker TS. 2003. Reovirus polymerase lambda 3 localized by cryo-electron microscopy of virions at a resolution of 7.6 A. Nat. Struct. Biol. 10:1011-1018.